A Nijmegen-based public-private partnership received 1.5 million Euro from the European Fund for Regional Development (EFRO).
With this grant, the consortium aims to develop novel therapeutics against mosquito-transmitted tropical infectious diseases, such as Malaria, dengue virus and Zika virus.
The consortium consists of the spinoff companies Protinhi Therapeutics, TropIQ Health Sciences, both based at the Novio Tech Campus, and scientists from Radboud University (dr. Martin Feiters, prof. Floris Rutjes) and Radboud University Medical Center (dr. Ronald van Rij, prof. Robert Sauerwein).
More information (in Dutch): read more.
Related news items
For Women in Science Rising Talent Prizes 2022 Open for applications8 December 2021
L’Oréal Netherlands, the Netherlands Commission for Unesco and the Royal Holland Society of Sciences and Humanities (KHMW) have joined hands to offer national prizes to young female researchers as part of the Netherlands L’Oréal-Unesco For Women in Science program. Deadline 20 January 2022.read more
DeepRank: a deep learning framework for data mining 3D protein-protein interfaces8 December 2021
Li Xue and colleagues recently published ''DeepRank, a deep learning framework for data mining 3D protein-protein structures'' on Nature Communications.read more
Johan van der Vlag chairs Scientific Advisory Board Mercurna8 December 2021
Johan van der Vlag will strengthen the development path of mCura1, Mercurna's lead formulation for chronic kidney disease as chair of the Scientific Advisory Board of the Biotech.read more